Last reviewed · How we verify
NCT04068207
Minocycline Treatment in Retinitis Pigmentosa
Completed
Phase 2
Last updated 27 December 2023
What this trial tests
Phase 2 trial testing Minocycline in Retinitis Pigmentosa in 35 participants. Completed in 1 December 2023.
Timeline
25 August 2019
Primary endpoint
31 January 2023
31 January 2023
1 December 2023
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 25 August 2019 |
| Primary completion | 31 January 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Minocycline (MINOCYCLINE) — full drug profile →
Conditions studied
- Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
- Inherited Retinal Dystrophy — all drugs for Inherited Retinal Dystrophy →
- Retina Disorder — all drugs for Retina Disorder →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 60, any sex, with Retinitis Pigmentosa or Inherited Retinal Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d), administered for 6 months, for the treatment of patients with retinitis pigments(RP).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting Microglia to Treat Degenerative Eye Diseases.
Wang SK, Cepko CL. · · 2022 · cited 44× · PMID 35251042 · DOI 10.3389/fimmu.2022.843558 -
Inherited Retinal Dystrophies: Role of Oxidative Stress and Inflammation in Their Physiopathology and Therapeutic Implications.
Pinilla I, Maneu V, Campello L, Fernández-Sánchez L, et al · · 2022 · cited 30× · PMID 35739983 · DOI 10.3390/antiox11061086 -
Optical coherence tomography in the evaluation of retinitis pigmentosa.
Oh JK, Nuzbrokh Y, Lima de Carvalho JR, Ryu J, et al · · 2020 · cited 22× · PMID 32552399 · DOI 10.1080/13816810.2020.1780619 -
Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial.
Chen Y, Pan Y, Xie Y, Shi Y, et al · · 2024 · cited 7× · PMID 39627217 · DOI 10.1038/s41392-024-02037-2
Verify or expand the search:
- PubMed search for NCT04068207
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Minocycline
Trials testing the same drug.
- NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
- NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
- NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
- NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
- NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting
Other recruiting trials for Retinitis Pigmentosa
Currently open trials in the same condition.
- NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
- NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04068207 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 27 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04068207.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing